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1.  Rationale 
Cancer is the second major cause of death after Heart Disease, and Alzheimer’s Disease (AD) is the 
third major cause of death with major, human and financial/economics trillion dollar consequences 
for the society. Nuclear Medicine is concerned with applications in Medicine of Nuclear Science and 
Engineering techniques and knowledge. Three major Nuclear Medicine techniques that are 
established for diagnostic and research purposes are:      
 Positron Emission Tomography (PET) and CAT/CT 
 Nuclear Magnetic Resonance Imaging (NMRI/ MRI). 
However, these three techniques have also major limitations in terms of either cost or image 
resolution, as well as patient irradiation in the case of CAT/CT and PET. On the other hand, Near 
Infrared Chemical Imaging Microspectroscopy and certain Fluorescence spectroscopic techniques 
are capable of single cancer cell and/or single molecule detection and/or imaging.   Such powerful 
capabilities, combined with low cost of diagnostics, make these novel techniques  very attractive 
means for early detection of diseases such as cancer and Alzheimer's, that are promising to reduce the 
fatality rate of patients through adequate diagnosis and treatment of such diseases at early stages.       
                                  2. Social Impact of AD on Caregivers 
 There are 15 million Alzheimer’s and dementia caregivers providing 17 billion hours of unpaid care 
valued at $202 billion; Current projections for 2030 are at least $1 Trillion ! 
 
(Source: Alzheimer’s Association 2011 Alzheimer’s Disease Facts and Figures) 
The social impact of AD healthcare  is thus arguably even greater than that of heart disease and 
cancers.  
                                 3. What is Alzheimer's Disease (AD)? 
This is a human brain disease that affects a significant fraction of the population over 62-65 years 
of age by causing problems with short-term memory, thinking, spatial orientation and behavior, 
worsening  over a time span of up to 20 years and in 60 to 80% of cases leading to dementia, “a 
general term for memory loss and other intellectual abilities serious enough to 
interfere with daily life” (Source: Alzheimer’s org.,  2011); in fact , serious enough to prevent a 
normal life without continuous help from caregivers! 
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                            4.  Positron Emission Tomography (PET) 
• PET is a Nuclear Medicine imaging technique which generates a 3D-image of the 
distribution of a positron-emitting radionuclide tracer introduced in the human body with 
a `marker’ molecule.  The PET detectors collect pairs of g-rays emitted from the positron 
annihilation with an electron, and scan through the positions of the radionuclide sources 
from locations within the human body:  e+ <--> e- ---- 2   ; example:   18F9  
18O8  + n  +
+   
            (positron:   J. P. Blaser, F. Boehm, and P. Marmier : Phys. Rev. (1949) 75:p.1953  
         ``The Positron Decay of F18 “). 
• Images of radionuclide activity distribution in 3-dimensional or 4-D space-time within the 
body are then reconstructed by fast computers to provide physicians with an image of, for 
example, the patients brain or the whole body. Recently, scans, such as for 3-D 
reconstructions are typically refined with the aid of  higher resolution, local CT  (CAT) scans 
also performed on the patient simultaneously with the PET scanning.  
• “A PET image is a 'photograph' of high-energy g-rays emitted from a positron-emitting 
radioisotope. Several such short-lived radioisotopes: 18F, 11C and 15O are made in a cyclotron, 
and a probe (for example, a drug, or water--in the case of O-15 of spin 1/2) is labeled and 
injected intravenously into a patient. The tracer is imaged in a scanner that comprises a large 
number of scintillation detectors. The collision of a positron with a nearby electron produces 
two -rays that are separated by 180 degrees. Two scintillation detectors that are separated 
by 180 degrees transmit a coincident signal when both are stimulated simultaneously. The 
photon energy that is absorbed by the detectors is re-emitted as visible light and detected by 
photomultiplier tubes.” (Nature Reviews Cancer, 4: 457-469; June 2004 ).   Image resolution 
is typically 5 to 10mm, which is low but almost adequate for early detection of certain 
cancers. 
            Which Nuclides and Markers can be used for PET/ SPECT detection of AD? 
• FDDNP: binds to plaques and `tangle’ deposits in the brain       
• PiB= Pittsburg marker :  claimed to bind specifically to aggregated  Abeta,  and 11C-labeled 
biomolecules  
• 18F- in FDG analogue of glucose for investigating sugar metabolism and diabetes-related risks 
of AD.   (NaF-- Sodium Fluoride for PET Bone Imaging) 
• 82Rb (Rubidium-82, Z=37) for cardiac PET scanning.  
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       Table 1B:  Other Radionuclides for PET Imaging: 
• Gallium-68   :  1.13h 
• Breast Cancer, Heart Imaging, Immunoscintigraphy, Molecular Imaging, Neuroendrocrine 
Tumors, Pancreatic Cancer, Alzheimer’s  ? 
• Iodine-124:    4.18d 
• Apoptosis, Cancer Biotherapy,  Gliomas, Heart Disease, Mediastinal Micrometastates, 
Scouting of Therapeutic Radioimmunoconjugates, Thyroid Cancer,  Alzheimer’s ? 
• Iron-52 :          8.28h 
• Anemia, Human Bone Marrow 
• Nitrogen-13:   9.97m 
• Ammonia Dog Studies, Coronary Artery Disease, Diabetes, Gamma Camera, Heart Disease, 
Imaging of Heart, Pancreas and Liver, Lupus Erythematosus, Myocardial Perfusion, 
Pulmonary Ventilation 
• Oxygen-15      122.s 
• Acute Brain Injury, Arterial Blood Flow, Brain Cancer, Oxygen Utilization, Brain Studies, 
Cerebral Blood Volume, Cerebral Responses, Coronary Artery Vasospasm, Coronary Reserve, 
Heart Disease, Ischemic Stroke Disease, Kinetics of Oxygen, Liver Cancer, Myocardial 
Viability, Oxygen Metabolism, Pain Control, Venous Ulceration, Alzheimer’s  ?  
• Rubidium-82:   1.26m 
• Heart Disease, Myocardial Perfusion, Sarcoidosis, Alzheimer’s  ? 
• Yttrium-86 :     14.74h 
• Distribution of Y90, Lung Cancer, Melanoma, Renal Cell Carcinoma 
• Zirconium-89:   3.27d 
• Brain Tumors, Head and Neck Cancers, non-Hodgkin's Lymphoma, Alzheimer’s ?  
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 According to Dr. Elliot Kolin, lead radiologist at WMI: "the NYU research team used PiB-PET with 
a fluorescent imaging agent called Pittsburgh Compound B that lights up clumps of a protein 
called beta amyloid (A-beta ) that are a characteristic finding of Alzheimer's disease.“      
Normal A-beta protein does not clump!  One notes the presence of modified A-beta clumps, or 
hydrophobic plaques, also in the frontal areas of the AD brain (most probably advanced AD) in 
his team’s scans.    
There are however microscopic changes of the neurons in the cortex of AD brains compared 
with those of the normal brain:  the modified A-beta clumps/plaques and/or ‘tangles’ are 
characteristic of AD.  Such microscopic evidence is at present the only medically accepted 
(post-mortem) confirmation of the AD diagnosis,  because the established Nuclear Medicine 
techniques currently in use for diagnosis in clinics and hospitals are unable to detect such 
microscopic changes until the AD is widespread in the brain, which is too late for adequate 
medical treatment of the disease. 
PiB-PET is claimed to detect structural changes associated with AD ! 
• 1. This is quite important because-- if it is firmly established for all AD type-- it may lead to 
some progress in understanding the disease, and perhaps also other kinds of dementia, 
hopefully leading to some treatments not at all available today! 
• 2. When combined with other types of PET scans it is hoped to link such structural changes 
with functional ones as well, and possibly correlate with AD-related cognitive 
impairement, such as the learning inabilities of AD patients related to short-term memory 
loss.  
• 3. It has been proposed based on genetic evidence from rare cases of AD--which are 
inherited-- that a specific gene (ApoE) and its  e4 allele are involved:  Basun, H., Grut, M., 
Winblad, B. & Lannfeldt, L. (1995). Apolipoprotein e4 allele and disease progression in patients 
with late onset Alzhiemer's disease. Neuroscience Letters, 183, 32-34; cited in: A. S. Macdonald 
and D. J. Pritchard, 2000).  
 This raises the possibility/question if in those AD cases that are not inherited through  a 
genetic mutation (activation of e4  ??) in ApoE- the Apolipoprotein  E Gene-- might also occur  
which would be perhaps induced through either metabolic or environmental factors that have 
not yet been either identified or suspected?  
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The latter, very important question cannot be investigated with the three, already established, 
Nuclear Medicine techniques discussed above but it is quite feasible by using Near Infrared 
Microspectroscopy/Fluorescence techniques that are capable of both single cell detection and 
single molecule imaging, thus making the diagnosis of AD and cancers a real possibility 
through affordable and noninvasive scanning of human populations, especially those at risk-- 
above age 60/62, male/female, respectively. 
              5. AD Pathology and Medical Diagnosis 
     AD Pathology is characterized at least by the following: 
• ``(a) senile plaques (deposits on the outside of neurons , consisting largely of the modified 
protein b-amyloid)—the adopted post-mortem criterion for confirming the diagnosis of AD; 
• (b) amyloid angiopathy (deposits of amyloid protein in the arteries of the brain); 
• (c) neurobrillary `tangles’ (dysfunctional connections between neurons); 
• (d) loss of neurons; 
• (e) decreased activity of choline acetyltransferase (an enzyme…involved in synaptic 
transmission)”; 
• (f) mutations in two genes labeled presenilin-1 (PS-1) and presenilin-2  (PS-2), which appear 
to be associated with AD, though the mechanisms remain so far unclear.  
(loc.cit.)  
 5.1. The Apolipoprotein E (ApoE) gene  involvement in AD 
• ``The ApoE e4 allele has been found to confer risk for AD in a dose related fashion, 
such that e4 homozygotes e4 /e4 ) are at a greater risk then e4 heterozygotes e2/e4 , 
e3/e4 ), who in turn are at greater risk than those without the e4 allele:”  
(Bickeboller et al., 1997; Corder et al., 1994; van Duijn et al., 1995; Farrer et al., 1997;  
Jarvik et al., 1996; Kuusisto et al., 1994; Lehtovirta et al., 1995; Mayeux et al., 1993;  
Myers et al., 1996; Poirier et al., 1993; Tsai et al., 1994).  
• Some studies have observed that the risk depends on age; ApoE e4 seems to have greatest 
effect at ages 60 to 70, tapering off at older ages:  
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Bickeboller et al., 1997; Corder et al., 1994; Farrer et al., 1997. 
• (d) It is also possible that the ApoE e4 allele is associated with an earlier onset of AD (not to 
be confused with the early-onset AD type—which is inherited, in rare cases,  i.e., e4 
homozygotes: e4/e4).  
5.2. The Modified tau-Protein in AD 
• Another hypothesis about AD causes-- that has gained momentum-- is the involvement of a 
modified/ shortened tau (t)-proteins that normally act as spacers between microtubules in 
the nutrient transport system of the nerve cells; it has been claimed that the modified t-
proteins aggregate thus causing the early onset of AD by `messing up’ the nutrient transport 
system of the nerve cells that die later for lack of sufficient nutrients. 
• Moreover, it has been claimed that the Ab plaques appear only at later stages of AD, and 
also that modified t’s are a better indicator than Ab plaques for early diagnosis of AD.   
One notes that the two hypothesis are not mutually exclusive, but one can envisage either 
5.1 or 5.2 being the first stage of Alzheimer’s, and the question which one occurs first in AD- 
if it does indeed occur-is a very important one for developing an efficient diagnosis and 
treatment of AD. 
               6. New Strategies 
6.1. Part I. Combining Techniques:  PET/CAT, MRI-NMRI/PET, MRI/CAT,…and Modeling: 
So far still has only limited success, but this is what most often happens in clinical diagnosis because 
it was an obvious first step, but with the risk of additional radiation doses that are not insignificant 
for repeated scanning, even if localized, by CAT/CT X-ray tomography.   
This is not the case for MRI diagnosis or scanning , but the latter does not have the high resolution 
of CAT/CT scans. 
6.2. Further, Novel Strategies:  
II.  Making and using antibodies for modified  Ab and t-proteins, combined with  
  III.  Novel Molecular Imaging, such as FT-NIR Microspectroscopy/SMD Fluorescence 
techniques/FSSC, and so on;  
IV. Improved AD Supercomputer Modeling,  (maybe also combined with)       
 V. Radioimmunotherapy (RIT) and Gene Therapy.  
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 6.2. III. Ilustration of NIRFS Detection of Tumors with NIR-emissive Polymerosomes in Rats 
 
Figure 1a.   Source:  GHOROGHCHIAN, P.  et al. 2009. In vivo fluorescence imaging: a personal 
perspective, NANOMEDICINE AND NANOBIOTECHNOLOGY , VOL 1 , ISSUE 2 (MARCH/APRIL 2009), 
156-167. DOI: 10.1002/wnan.7  http://wires.wiley.com/WileyCDA/WiresArticle/wisId-
WNAN7.html :  Left a. & b: NIRFS detection of rat tumors. 
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Figure 1b: Left a. & b: NIRFS detection of rat tumors. 
150-nm diameter nondegradable polymerosomes (composed of a 1 : 1 molar mixture 
of PEO30-b-PBD46 and PEO80-b-PBD125; 1 : 40 NIRF-to-total-polymer molar ratio) 
were imaged after tail-vein injection of tumor-bearing mice utilizing a GE eXplore 
Optix instrument (λex = 785 nm, λem = 830–900 nm). 
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 6.3. Major Obstacles: 
1.  Failed AD Clinical trials in UK with an attempted `vaccination’.   
2. The high cost of screening large number of patients by PET/CAT and/or NMRI. 
Possible answers in the near future: 
  Improved Modeling may help, for example, with designing new clinical trials 
and animal studies that are now needed.  This is a low-cost exercise involving 
minds, supercomputers, data mining and mega-database analyses.  
  Novel molecular imaging techniques that are much less expensive than PET/CT 
and MRI/PET.  An example already employed for early discovery of cancers is 
Near Infrared Fluorescence Spectroscopy (NIRFS). 
  RIT or Radioimmunotherapy where the goal is to target with radioisotopes or 
markers  the affected cells or aggregated molecules without harming the 
healthy cells. This is also known as cell-directed therapy.  In cancers, RIT success 
was achieved with the radioisotopes irridium-192 and iodine-125 to treat 
lymphomas and thyroid tumors, respectively.   
                                                         7. CONCLUSION 
III. FT-NIR/Fluorescence early diagnosis and discovery of AD and cancers is the most 
promising and powerful approach by comparison with all the others! 
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                                               Appendix: 
<<Structure and morphology of the Alzheimer's amyloid fibrils: 
60 
Microscopy Res Tech. 2005 Jul;67(3-4):210-7. 
Structure and morphology of the Alzheimer's amyloid fibril. 
Stromer T, Serpell LC. Department of Biochemistry, School of Life Sciences, University of 
Sussex, Falmer, BN1 9QG, UK. 
 
Abstract 
―Amyloid fibrils are deposited in a number of diseases, including Alzheimer's disease, 
Type 2 diabetes, and the transmissible spongiform encephalopathies (TSE). These insoluble 
deposits are formed from normally soluble proteins that assemble to form fibrous aggregates that 
accumulate in the tissues. Electron microscopy has been used as a tool to examine the structure and 
morphology of these aggregates from ex vivo materials, but predominantly from synthetic amyloid 
fibrils assembled from proteins or peptides in vitro. Electron microscopy has shown that the fibrils 
are straight, unbranching, and are of a similar diameter (60-100 Angstroms) irrespective of the 
precursor protein. Image processing has enhanced electron micrographs to show that amyloid fibrils 
appear to be composed of protofilaments wound around one another. In combination with other 
techniques, including X-ray fiber diffraction and solid state NMR, electron microscopy has 
revealed that the internal structure of the amyloid fibril is a ladder of beta-sheet structure 
arranged in a cross-beta conformation.‖ >> 
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